Skip to main content
Top
Published in: BMC Geriatrics 1/2022

Open Access 01-12-2022 | Research

An international Delphi consensus process to determine a common data element and core outcome set for frailty: FOCUS (The Frailty Outcomes Consensus Project)

Authors: Jeanette C. Prorok, Paula R. Williamson, Beverley Shea, Darryl Rolfson, Leocadio Rodriguez Mañas, Matteo Cesari, Perry Kim, John Muscedere

Published in: BMC Geriatrics | Issue 1/2022

Login to get access

Abstract

Background

Despite increased recognition of frailty and its importance, high quality evidence to guide decision-making is lacking. There has been variation in reported data elements and outcomes which makes it challenging to interpret results across studies as well as to generalize research findings. The creation of a frailty core set, consisting of a minimum set of data elements and outcomes to be measured in all frailty studies, would allow for findings from research and translational studies to be collectively analyzed to better inform care and decision-making. To achieve this, the Frailty Outcomes Consensus Project was developed to reach consensus from the international frailty community on a set of common data elements and core outcomes for frailty.

Methods

An international steering committee developed the methodology and the consensus process to be followed. The committee formulated the initial list of data elements and outcomes. Participants from across the world were invited to take part in the Delphi consensus process. The Delphi consisted of three rounds. Following review of data after three rounds, a final ranking round of data elements and outcomes was conducted. A required retention rate of 80% between rounds was set a priori.

Results

One hundred and eighty-four panelists from 25 different countries participated in the first round of the Delphi consensus process. This included researchers, clinicians, administrators, older adults, and caregivers. The retention rate between rounds was achieved. Data elements and outcomes forming primary and secondary core sets were identified, within the domains of participant characteristics, physical performance, physical function, physical health, cognition and mental health, socioenvironmental circumstances, frailty measures, and other.

Conclusion

It is anticipated that implementation and uptake of the frailty core set will enable studies to be collectively analyzed to better inform care for persons living with frailty and ultimately improve their outcomes. Future work will focus on identification of measurement tools to be used in the application of the frailty core set.
Appendix
Available only for authorised users
Literature
2.
go back to reference WHO Clinical Consortium on Healthy Ageing. Report of consortium meeting 1–2 December 2016 in Geneva, Switzerland. Geneva: World Health Organization; 2017 (WHO/FWC/ALC/17.2) WHO Clinical Consortium on Healthy Ageing. Report of consortium meeting 1–2 December 2016 in Geneva, Switzerland. Geneva: World Health Organization; 2017 (WHO/FWC/ALC/17.2)
3.
go back to reference Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquín B, Sánchez-Castellano C, Sánchez-García E. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61(5):734–8.CrossRef Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquín B, Sánchez-Castellano C, Sánchez-García E. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61(5):734–8.CrossRef
4.
go back to reference Lindley RI. Drug trials for older people. J Gerontol A Biomed Sci Med Sci. 2011;67(2):152–7. Lindley RI. Drug trials for older people. J Gerontol A Biomed Sci Med Sci. 2011;67(2):152–7.
5.
go back to reference van Deudekom FJ, Postmus I, van der Ham DJ, Pothof AB, Broekhuizen K, Blauw GJ, et al. External validity of randomized controlled trials in older adults, a systematic review. PloS one. 2017;12(3):e0174053.CrossRef van Deudekom FJ, Postmus I, van der Ham DJ, Pothof AB, Broekhuizen K, Blauw GJ, et al. External validity of randomized controlled trials in older adults, a systematic review. PloS one. 2017;12(3):e0174053.CrossRef
7.
go back to reference Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials. 2007;8(1):38.CrossRef Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials. 2007;8(1):38.CrossRef
8.
go back to reference Ioannidis JP, Horbar JD, Ovelman CM, Brosseau Y, Thorlund K, Buus-Frank ME, et al. Completeness of main outcomes across randomized trials in entire discipline: survey of chronic lung disease outcomes in preterm infants. Bmj. 2015;350:h72.CrossRef Ioannidis JP, Horbar JD, Ovelman CM, Brosseau Y, Thorlund K, Buus-Frank ME, et al. Completeness of main outcomes across randomized trials in entire discipline: survey of chronic lung disease outcomes in preterm infants. Bmj. 2015;350:h72.CrossRef
9.
go back to reference Harburg L, McCormack E, Kenney K, Moore C, Yang K, Vos P, et al. Reliability of the NINDS common data elements cranial tomography (CT) rating variables for traumatic brain injury (TBI). Brain Inj. 2017;31(2):174–84.CrossRef Harburg L, McCormack E, Kenney K, Moore C, Yang K, Vos P, et al. Reliability of the NINDS common data elements cranial tomography (CT) rating variables for traumatic brain injury (TBI). Brain Inj. 2017;31(2):174–84.CrossRef
10.
go back to reference Saver JL, Warach S, Janis S, Odenkirchen J, Becker K, Benavente O, et al. Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project. Stroke. 2012;43(4):967–73.CrossRef Saver JL, Warach S, Janis S, Odenkirchen J, Becker K, Benavente O, et al. Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project. Stroke. 2012;43(4):967–73.CrossRef
12.
go back to reference Muscedere J, Afilalo J, de Carvalho IA, Cesari M, Clegg A, Eriksen HE, Williamson PR. Moving towards common data elements and core outcome measures in frailty research. J Frailty Aging. 2020;9(1):14–22.PubMed Muscedere J, Afilalo J, de Carvalho IA, Cesari M, Clegg A, Eriksen HE, Williamson PR. Moving towards common data elements and core outcome measures in frailty research. J Frailty Aging. 2020;9(1):14–22.PubMed
15.
go back to reference Macefield RC, Boulind CE, Blazeby JM. Selecting and measuring optimal outcomes for randomised controlled trials in surgery. Langenbecks Arch Surg. 2014;399(3):263–72.CrossRef Macefield RC, Boulind CE, Blazeby JM. Selecting and measuring optimal outcomes for randomised controlled trials in surgery. Langenbecks Arch Surg. 2014;399(3):263–72.CrossRef
16.
go back to reference Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Tugwell P. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13(1):1–8.CrossRef Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Tugwell P. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13(1):1–8.CrossRef
17.
go back to reference Biggane AM, Brading L, Ravaud P, Young B, Williamson PR. Survey indicated that core outcome set development is increasingly including patients, being conducted internationally and using Delphi surveys. Trials. 2018;19(1):1–6.CrossRef Biggane AM, Brading L, Ravaud P, Young B, Williamson PR. Survey indicated that core outcome set development is increasingly including patients, being conducted internationally and using Delphi surveys. Trials. 2018;19(1):1–6.CrossRef
18.
go back to reference Young B, Bagley H. Including patients in core outcome set development: issues to consider based on three workshops with around 100 international delegates. Res Involvement Engagement. 2016;2(1):1–13.CrossRef Young B, Bagley H. Including patients in core outcome set development: issues to consider based on three workshops with around 100 international delegates. Res Involvement Engagement. 2016;2(1):1–13.CrossRef
19.
go back to reference Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR. Core outcome Set-STAndards for development: the COS-STAD recommendations. PLoS Med. 2017;14(11):e1002447.CrossRef Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR. Core outcome Set-STAndards for development: the COS-STAD recommendations. PLoS Med. 2017;14(11):e1002447.CrossRef
20.
go back to reference Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, Terwee CB. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set”–a practical guideline. Trials. 2016;17(1):1–10.CrossRef Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, Terwee CB. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set”–a practical guideline. Trials. 2016;17(1):1–10.CrossRef
Metadata
Title
An international Delphi consensus process to determine a common data element and core outcome set for frailty: FOCUS (The Frailty Outcomes Consensus Project)
Authors
Jeanette C. Prorok
Paula R. Williamson
Beverley Shea
Darryl Rolfson
Leocadio Rodriguez Mañas
Matteo Cesari
Perry Kim
John Muscedere
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2022
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-022-02993-w

Other articles of this Issue 1/2022

BMC Geriatrics 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine